Taurine and aging: what the Singh 2023 Science work and the human data actually show

In 2023 a study in Science set off a wave of headlines: taurine, the cheap amino acid in energy drinks, might be an aging molecule. The paper was serious, multi-species, and carefully done. But the story that reached the public — “taurine reverses aging” — ran far ahead of what it showed, and the human side of the claim has since been directly challenged. Here is what the work actually established and where it stopped.

What the 2023 Science paper showed

Singh and colleagues reported that taurine concentrations decline with age across several species, and — the headline result — that supplementing taurine extended lifespan and improved healthspan markers in mice, with supporting healthspan effects in worms and monkeys.^[1]That is a genuinely strong preclinical result: a measured age-related decline, plus a lifespan benefit from restoring the molecule in a mammalian model. It is exactly the kind of finding that justifies serious follow-up. It is also entirely animal lifespan data — no human lifespan or healthspan outcome was demonstrated.

The premise that didn't replicate in humans

The single most important development since came in 2025, when a large analysis using longitudinal human and non-human-primate data examined whether taurine actually behaves as an aging biomarker in people. It found that circulating taurine does not reliably decline with age in humans — the levels were highly variable between individuals and did not track a clean downward trajectory.^[2]This matters enormously, because the entire human pitch rests on the premise that taurine falls as we age and therefore needs replacing. If the premise doesn't hold in people, the “restore what you've lost” logic loses its foundation. The animal lifespan result stands; its human extrapolation is now openly contested.

What taurine supplementation does do in humans

Separate from the aging claim, taurine has been studied in humans for specific endpoints, with modest results. A randomized, double-blind, placebo-controlled trial found taurine supplementation lowered blood pressure and improved vascular function in people with prehypertension.^[3]A meta-analysis of randomized trials reported small favorable effects on blood pressure and lipid measures, with effects on body weight less consistent.^[4] And a meta-analysis of taurine on cognitive function found the human evidence limited and inconclusive.^[5] The pattern is consistent: taurine looks safe and shows small, real effects on a few cardiometabolic surrogates — and none of that is the same as slowing human aging.

The leap the headlines made

The load-bearing distinction is between a lifespan effect in mice and an anti-aging effect in people. The 2023 paper delivered the former. It did not deliver the latter, and the 2025 human biomarker work actively undercuts the bridge between them by questioning whether taurine even declines with age in humans. The cardiometabolic trials, meanwhile, measure blood pressure and lipids over weeks — not aging over years.

The honest bottom line

Taurine's aging evidence is strong in animals and unproven — arguably contested — in humans. What is supported: a robust mouse lifespan result, and small effects on human blood pressure and lipids. What is not supported: that taurine slows, prevents, or reverses human aging, or that people are walking around taurine-deficient in a way supplementation fixes. Taurine is cheap and well-tolerated, so the downside of trying it is low — but it should be taken understanding that the anti-aging claim rests on mouse data and a human premise that hasn't held up.